Vancouver, BC - November 28, 2017 - Medipure Pharmaceuticals, a biopharmaceutical incubator committed to discovering and developing proprietary cannabinoid-derived prescription medications, is pleased to announce the addition of Dr. Gerald Zamponi to the company’s Scientific Advisory Board.

Dr. Zamponi joins the company with vast experience as an expert in molecular physiology and pharmacology of ion channels and receptors and the role they play in pain signaling.

"We are excited to have Dr. Zamponi join our scientific advisory board and look forward to working with him on harnessing his experience and scientific expertise to advise Medipure on future developments within our proprietary cannabinoid formulations," stated Medipure CEO, Boris Weiss. "He joins a profoundly talented group on our scientific advisory board and we look forward to the innovations that are to come."

Dr. Zamponi received his PhD in neuroscience from the University of Calgary. He earned his post-doctorate from the University of British Columbia and returned to the University of Calgary where he was appointed as an assistant professor. Since then, he has been promoted to Associate Professor, full Professor and then the Head of the Physiology and Pharmacology department. Currently he is the Senior Associate Dean for Research at the Cumming School of Medicine, University of Calgary. He has authored more than 260 peer-reviewed articles and has given more than 200 invited presentations. He is a Canada Research Chair in Molecular Neuroscience, and Fellow of the Royal Society of Canada and the Canadian Academy of Health Sciences.

Medipure Pharmaceuticals is a biopharmaceutical incubator committed to discovering and developing proprietary endocannabinoid system-based prescription drugs for targeted diseases by regulating specific molecular mechanisms. Our core products target specific disease areas including pain management, mood disorders/anxiety, nausea, appetite, oncology, arthritis and dermatology.

Medipure Pharmaceuticals' research and development is focused on having the greatest impact and benefit for patients worldwide. At the same time, we aim to make sure that our products are approved by regulators and well-understood by physicians, healthcare providers and prospective patients.

Public Relations Contact:
Aaron Wood
CMW Media
P. 413-627-2468